| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1827 | 2020 |
| Lenalidomide induces ubiquitination and degradation of CK1α in del (5q) MDS J Krönke, EC Fink, PW Hollenbach, KJ MacBeth, SN Hurst, ND Udeshi, ... Nature 523 (7559), 183-188, 2015 | 800 | 2015 |
| Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment K El-Shami, E Griffiths, M Streiff The Oncologist 12 (5), 518-523, 2007 | 332 | 2007 |
| Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology PL Greenberg, RM Stone, A Al-Kali, SK Barta, R Bejar, JM Bennett, ... Journal of the National Comprehensive Cancer Network 15 (1), 60-87, 2017 | 325 | 2017 |
| Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study JPJ Issa, G Roboz, D Rizzieri, E Jabbour, W Stock, C O'Connell, K Yee, ... The lancet oncology 16 (9), 1099-1110, 2015 | 315 | 2015 |
| DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes EA Griffiths, SD Gore Seminars in hematology 45 (1), 23-30, 2008 | 243 | 2008 |
| Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer K Odunsi, J Matsuzaki, SR James, P Mhawech-Fauceglia, T Tsuji, A Miller, ... Cancer immunology research 2 (1), 37-49, 2014 | 189 | 2014 |
| Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study G Garcia-Manero, EA Griffiths, DP Steensma, GJ Roboz, R Wells, ... Blood, The Journal of the American Society of Hematology 136 (6), 674-683, 2020 | 172 | 2020 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 169 | 2021 |
| Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial HM Kantarjian, GJ Roboz, PL Kropf, KWL Yee, CL O'Connell, R Tibes, ... The Lancet Oncology 18 (10), 1317-1326, 2017 | 169 | 2017 |
| MS-qFRET: a quantum dot-based method for analysis of DNA methylation VJ Bailey, H Easwaran, Y Zhang, E Griffiths, SA Belinsky, JG Herman, ... Genome research 19 (8), 1455-1461, 2009 | 153 | 2009 |
| Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology J Crawford, PS Becker, JO Armitage, DW Blayney, J Chavez, P Curtin, ... Journal of the National Comprehensive Cancer Network 15 (12), 1520-1541, 2017 | 137 | 2017 |
| Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation EA Griffiths, SD Gore, C Hooker, MA McDevitt, JE Karp, BD Smith, ... Leukemia & lymphoma 51 (9), 1711-1719, 2010 | 114 | 2010 |
| Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia A Emadi, R Faramand, B Carter‐Cooper, S Tolu, LA Ford, RG Lapidus, ... American journal of hematology 90 (5), E77-E79, 2015 | 111 | 2015 |
| Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts P Srivastava, BE Paluch, J Matsuzaki, SR James, G Collamat-Lai, ... Leukemia research 38 (11), 1332-1341, 2014 | 98 | 2014 |
| Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies P Ghione, JJ Gu, K Attwood, P Torka, S Goel, S Sundaram, C Mavis, ... Blood, The Journal of the American Society of Hematology 138 (9), 811-814, 2021 | 97 | 2021 |
| Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial G Garcia-Manero, G Roboz, K Walsh, H Kantarjian, E Ritchie, P Kropf, ... The Lancet Haematology 6 (6), e317-e327, 2019 | 91 | 2019 |
| NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome EA Griffiths, P Srivastava, J Matsuzaki, Z Brumberger, ES Wang, J Kocent, ... Clinical Cancer Research 24 (5), 1019-1029, 2018 | 91 | 2018 |
| COVID-19 vaccination and breakthrough infections in patients with cancer AL Schmidt, C Labaki, CY Hsu, Z Bakouny, N Balanchivadze, SA Berg, ... Annals of oncology 33 (3), 340-346, 2022 | 90 | 2022 |
| NCCN guidelines insights: hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines PS Becker, EA Griffiths, LM Alwan, K Bachiashvili, A Brown, R Cool, ... Journal of the National Comprehensive Cancer Network 18 (1), 12-22, 2020 | 85 | 2020 |
